Tag Archives: bug

#437778 A Bug-Sized Camera for Bug-Sized Robots ...

As if it’s not hard enough to make very small mobile robots, once you’ve gotten the power and autonomy all figured out (good luck with that), your robot isn’t going to be all that useful unless it can carry some payload. And the payload that everybody wants robots to carry is a camera, which is of course a relatively big, heavy, power hungry payload. Great, just great.

This whole thing is frustrating because tiny, lightweight, power efficient vision systems are all around us. Literally, all around us right this second, stuffed into the heads of insects. We can’t make anything quite that brilliant (yet), but roboticists from the University of Washington, in Seattle, have gotten us a bit closer, with the smallest wireless, steerable video camera we’ve ever seen—small enough to fit on the back of a microbot, or even a live bug.

To make a camera this small, the UW researchers, led by Shyam Gollakota, a professor of computer science and engineering, had to start nearly from scratch, primarily because existing systems aren’t nearly so constrained by power availability. Even things like swallowable pill cameras require batteries that weigh more than a gram, but only power the camera for under half an hour. With a focus on small size and efficiency, they started with an off-the-shelf ultra low-power image sensor that’s 2.3 mm wide and weighs 6.7 mg. They stuck on a Bluetooth 5.0 chip (3 mm wide, 6.8 mg), and had a fun time connecting those two things together without any intermediary hardware to broadcast the camera output. A functional wireless camera also requires a lens (20 mg) and an antenna, which is just 5 mm of wire. An accelerometer is useful so that insect motion can be used to trigger the camera, minimizing the redundant frames that you’d get from a robot or an insect taking a nap.

Photo: University of Washington

The microcamera developed by the UW researchers can stream monochrome video at up to 5 frames per second to a cellphone 120 meters away.

The last bit to make up this system is a mechanically steerable “head,” weighing 35 mg and bringing the total weight of the wireless camera system to 84 mg. If the look of the little piezoelectric actuator seems familiar, you have very good eyes because it’s tiny, and also, it’s the same kind of piezoelectric actuator that the folks at UW use to power their itty bitty flying robots. It’s got a 60-degree panning range, but also requires a 96 mg boost converter to function, which is a huge investment in size and weight just to be able to point the camera a little bit. But overall, the researchers say that this pays off, because not having to turn the entire robot (or insect) when you want to look around reduces the energy consumption of the system as a whole by a factor of up to 84 (!).

Photo: University of Washington

Insects are very mobile platforms for outdoor use, but they’re also not easy to steer, so the researchers also built a little insect-scale robot that they could remotely control while watching the camera feed. As it turns out, this seems to be the smallest, power-autonomous terrestrial robot with a camera ever made.

This efficiency means that the wireless camera system can stream video frames (160×120 pixels monochrome) to a cell phone up to 120 meters away for up to 6 hours when powered by a 0.5-g, 10-mAh battery. A live, first-bug view can be streamed at up to 5 frames per second. The system was successfully tested on a pair of darkling beetles that were allowed to roam freely outdoors, and the researchers noted that they could also mount it on spiders or moths, or anything else that could handle the payload. (The researchers removed the electronics from the insects after the experiments and observed no noticeable adverse effects on their behavior.)

The researchers are already thinking about what it might take to put a wireless camera system on something that flies, and it’s not going to be easy—a bumblebee can only carry between 100 and 200 mg. The power system is the primary limitation here, but it might be possible to use a solar cell to cut down on battery requirements. And the camera itself could be scaled down as well, by using a completely custom sensor and a different type of lens. The other thing to consider is that with a long-range wireless link and a vision system, it’s possible to add sophisticated vision-based autonomy to tiny robots by doing the computation remotely. So, next time you see something scuttling across the ground, give it another look, because it might be looking right back at you.

“Wireless steerable vision for live insects and insect-scale robots,” by Vikram Iyer, Ali Najafi, Johannes James, Sawyer Fuller, and Shyamnath Gollakota from the University of Washington, is published in Science Robotics. Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots

#437326 Researchers one step closer to ...

If you want to enhance a locust to be used as a bomb-sniffing bug, there are a few technical challenges that need solving before sending it into the field. Continue reading

Posted in Human Robots

#436146 Video Friday: Kuka’s Robutt Is a ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

ARSO 2019 – October 31-1, 2019 – Beijing, China
ROSCon 2019 – October 31-1, 2019 – Macau
IROS 2019 – November 4-8, 2019 – Macau
Let us know if you have suggestions for next week, and enjoy today’s videos.

Kuka’s “robutt” can, according to the company, simulate “thousands of butts in the pursuit of durability and comfort.” Two of the robots are used at a Ford development center in Germany to evaluate new car seats. The tests are quite exhaustive, consisting of around 25,000 simulated sitting motions for each new seat design.” Or as Kuka puts it, “Pleasing all the butts on the planet is serious business.”

[ Kuka ]

Here’s a clever idea: 3D printing manipulators, and then using the 3D printer head to move those manipulators around and do stuff with them:

[ Paper ]

Two former soldiers performed a series of tests to see if the ONYX Exoskeleton gave them extra strength and endurance in difficult environments.

So when can I rent one of these to help me move furniture?

[ Lockheed ]

One of the defining characteristics of legged robots in general (and humanoid robots in particular) is the ability of walking on various types of terrain. In this video, we show our humanoid robot TORO walking dynamically over uneven (on grass outside the lab), rough (large gravel), and compliant terrain (a soft gym mattress). The robot can maintain its balance, even when the ground shifts rapidly under foot, such as when walking over gravel. This behaviour showcases the torque-control capability of quickly adapting the contact forces compared to position control methods.

An in-depth discussion of the current implementation is presented in the paper “Dynamic Walking on Compliant and Uneven Terrain using DCM and Passivity-based Whole-body Control”.

[ DLR RMC ]

Tsuki is a ROS-enabled quadruped designed and built by Lingkang Zhang. It’s completely position controlled, with no contact sensors on the feet, or even an IMU.

It can even do flips!

[ Tsuki ]

Thanks Lingkang!

TRI CEO Dr. Gill Pratt presents TRI’s contributions to Toyota’s New “LQ” Concept Vehicle, which includes onboard artificial intelligence agent “Yui” and LQ’s automated driving technology.

[ TRI ]

Hooman Hedayati wrote in to share some work (presented at HRI this year) on using augmented reality to make drone teleoperation more intuitive. Get a virtual drone to do what you want first, and then the real drone will follow.

[ Paper ]

Thanks Hooman!

You can now order a Sphero RVR for $250. It’s very much not spherical, but it does other stuff, so we’ll give it a pass.

[ Sphero ]

The AI Gamer Q56 robot is an expert at whatever this game is, using AI plus actual physical control manipulation. Watch until the end!

[ Bandai Namco ]

We present a swarm of autonomous flying robots for the exploration of unknown environments. The tiny robots do not make maps of their environment, but deal with obstacles on the fly. In robotics, the algorithms for navigating like this are called “bug algorithms”. The navigation of the robots involves them first flying away from the base station and later finding their way back with the help of a wireless beacon.

[ MAVLab ]

Okay Soft Robotics you successfully and disgustingly convinced us that vacuum grippers should never be used for food handling. Yuck!

[ Soft Robotics ]

Beyond the asteroid belt are “fossils of planet formation” known as the Trojan asteroids. These primitive bodies share Jupiter’s orbit in two vast swarms, and may hold clues to the formation and evolution of our solar system. Now, NASA is preparing to explore the Trojan asteroids for the first time. A mission called Lucy will launch in 2021 and visit seven asteroids over the course of twelve years – one in the main belt and six in Jupiter’s Trojan swarms.

[ NASA ]

I’m not all that impressed by this concept car from Lexus except that it includes some kind of super-thin autonomous luggage-carrying drone.

The LF-30 Electrified also carries the ‘Lexus Airporter’ drone-technology support vehicle. Using autonomous control, the Lexus Airporter is capable of such tasks as independently transporting baggage from a household doorstep to the vehicle’s luggage area.

[ Lexus ]

Vision 60 legged robot managing unstructured terrain without vision or force sensors in its legs. Using only high-transparency actuators and 2kHz algorithmic stability control… 4-limbs and 12-motors with only a velocity command.

[ Ghost Robotics ]

Tech United Eindhoven is looking good for RoboCup@Home 2020.

[ Tech United ]

Penn engineers participated in the Subterranean (SubT) Challenge hosted by DARPA, the Defense Advanced Research Projects Agency. The goal of this Challenge is for teams to develop automated systems that can work in underground environments so they could be deployed after natural disasters or on dangerous search-and-rescue missions.

[ Team PLUTO ]

It’s BeetleCam vs White Rhinos in Kenya, and the White Rhinos don’t seem to mind at all.

[ Will Burrard-Lucas ] Continue reading

Posted in Human Robots

#436094 Agility Robotics Unveils Upgraded Digit ...

Last time we saw Agility Robotics’ Digit biped, it was picking up a box from a Ford delivery van and autonomously dropping it off on a porch, while at the same time managing to not trip over stairs, grass, or small children. As a demo, it was pretty impressive, but of course there’s an enormous gap between making a video of a robot doing a successful autonomous delivery and letting that robot out into the semi-structured world and expecting it to reliably do a good job.

Agility Robotics is aware of this, of course, and over the last six months they’ve been making substantial improvements to Digit to make it more capable and robust. A new video posted today shows what’s new with the latest version of Digit—Digit v2.

We appreciate Agility Robotics foregoing music in the video, which lets us hear exactly what Digit sounds like in operation. The most noticeable changes are in Digit’s feet, torso, and arms, and I was particularly impressed to see Digit reposition the box on the table before grasping it to make sure that it could get a good grip. Otherwise, it’s hard to tell what’s new, so we asked Agility Robotics’ CEO Damion Shelton to get us up to speed.

IEEE Spectrum: Can you summarize the differences between Digit v1 and v2? We’re particularly interested in the new feet.

Damion Shelton: The feet now include a roll degree of freedom, so that Digit can resist lateral forces without needing to side step. This allows Digit v2 to balance on one foot statically, which Digit v1 and Cassie could not do. The larger foot also dramatically decreases load per unit area, for improved performance on very soft surfaces like sand.

The perception stack includes four Intel RealSense cameras used for obstacle detection and pick/place, plus the lidar. In Digit v1, the perception systems were brought up incrementally over time for development purposes. In Digit v2, all perception systems are active from the beginning and tied to a dedicated computer. The perception system is used for a number of additional things beyond manipulation, which we’ll start to show in the next few weeks.

The torso changes are a bit more behind-the-scenes. All of the electronics in it are now fully custom, thermally managed, and environmentally sealed. We’ve also included power and ethernet to a payload bay that can fit either a NUC or Jetson module (or other customer payload).

What exactly are we seeing in the video in terms of Digit’s autonomous capabilities?

At the moment this is a demonstration of shared autonomy. Picking and placing the box is fully autonomous. Balance and footstep placement are fully autonomous, but guidance and obstacle avoidance are under local teleop. It’s no longer a radio controller as in early videos; we’re not ready to reveal our current controller design but it’s a reasonably significant upgrade. This is v2 hardware, so there’s one more full version in development prior to the 2020 launch, which will expand the autonomy envelope significantly.

“This is a demonstration of shared autonomy. Picking and placing the box is fully autonomous. Balance and footstep placement are fully autonomous, but guidance and obstacle avoidance are under local teleop. It’s no longer a radio controller as in early videos; we’re not ready to reveal our current controller design but it’s a reasonably significant upgrade”
—Damion Shelton, Agility Robotics

What are some unique features or capabilities of Digit v2 that might not be obvious from the video?

For those who’ve used Cassie robots, the power-up and power-down ergonomics are a lot more user friendly. Digit can be disassembled into carry-on luggage sized pieces (give or take) in under 5 minutes for easy transport. The battery charges in-situ using a normal laptop-style charger.

I’m curious about this “stompy” sort of gait that we see in Digit and many other bipedal robots—are there significant challenges or drawbacks to implementing a more human-like (and presumably quieter) heel-toe gait?

There are no drawbacks other than increased complexity in controls and foot design. With Digit v2, the larger surface area helps with the noise, and v2 has similar or better passive-dynamic performance as compared to Cassie or Digit v1. The foot design is brand new, and new behaviors like heel-toe are an active area of development.

How close is Digit v2 to a system that you’d be comfortable operating commercially?

We’re on track for a 2020 launch for Digit v3. Changes from v2 to v3 are mostly bug-fix in nature, with a few regulatory upgrades like full battery certification. Safety is a major concern for us, and we have launch customers that will be operating Digit in a safe environment, with a phased approach to relaxing operational constraints. Digit operates almost exclusively under force control (as with cobots more generally), but at the moment we’ll err on the side of caution during operation until we have the stats to back up safety and reliability. The legged robot industry has too much potential for us to screw it up by behaving irresponsibly.

It will be a while before Digit (or any other humanoid robot) is operating fully autonomously in crowds of people, but there are so many large market opportunities (think indoor factory/warehouse environments) to address prior to that point that we expect to mature the operational safety side of things well in advance of having saturated the more robot-tolerant markets.

[ Agility Robotics ] Continue reading

Posted in Human Robots